Replay partners with MD Anderson’s Katy Rezvani, heads to clinic with new TCR NK cell company
Hub-and-spoke company Replay has launched a new cell therapy company called Syena, co-founded by NK cell leader Katy Rezvani of the University of Texas MD Anderson Cancer Center.
Syena plans to put Rezvani’s T cell receptor natural killer, or TCR NK, cell therapies into a Phase I trial in the second quarter of the year. That would make it the first to bring a TCR NK cell therapy into the clinic, Rezvani told Endpoints News. Rezvani added that they’re working on an IND package to submit to the FDA, which should happen “in the next couple of weeks or so.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.